The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo
Open accessAbstract
Albumin is a multifunctional transport protein that binds a wide variety of endogenous substances and drugs. Insulins with affinity for albumin were engineered by acylation of the epsilon-amino group of LysB29 with saturated fatty acids containing 10-16 carbon atoms. The association constants for binding of the fatty acid acylated insulins to human albumin are in the order of 10(4)-10(5) M-1. The binding apparently involves both non-polar and ionic interactions with the protein. The acylated insulins bind at the long-chain fatty acid binding sites, but the binding affinity is lower than that of the free fatty acids and depends to a relatively small degree on the number of carbon atoms in the fatty acid chain. Differences in affinity of the acylated insulins for albumin are reflected in the relative timing of the blood-glucose-lowering effect after subcutaneous injection into rabbits. The acylated insulins provide a breakthrough in the search for soluble, prolonged-action insulin preparations for basal delivery of the hormone to the diabetic patient. We conclude that the biochemical concept of albumin binding can be applied to protract the effect of insulin, and suggest that derivatization with albumin-binding ligands could be generally applicable to prolong the action profile of peptide drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atomic structure and chemistry of human serum albumin
He, X. M., & Carter, D. C. (1992) · Nature · doi:10.1038/358209a0 · Cited by 3,824
Carter, D. C., & Ho, J. X. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60640-3 · Cited by 3,187
Peters, T. (1985) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60065-0 · Cited by 2,181
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Monomeric insulins obtained by protein engineering and their medical implications
Brange, J., Ribel, U., Hansen, J. F., Dodson, G., Hansen, M. T., Havelund, S., Melberg, S. G., Norris, F., Norris, K., Snel, L., et al. (1988) · Nature · doi:10.1038/333679a0 · Cited by 488
Self-citationStructure and ligand binding properties of human serum albumin.
Kragh‐Hansen, U. (1990) · PubMed · Cited by 454
[13] The meaning of scatchard and hill plots
Dahlquist, F. W. (1978) · Methods in Enzymology · doi:10.1016/s0076-6879(78)48015-2 · Cited by 310
Long chain fatty acid binding to human plasma albumin.
Ashbrook, J., Spector, A., Santos, E., & Fletcher, J. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41721-3 · Cited by 275
Black, R. L. (1984) · Military Medicine · doi:10.1093/milmed/149.3.161a · Cited by 247
Physical Chemistry: with Applications to the Life Sciences
Eisenberg, D. S., & Crothers, D. M. (1979) · Andalas University Repository (Andalas University) · Cited by 219
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Protein drug stability: a formulation challenge
Frokjaer, S., & Otzen, D. E. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1695 · Cited by 1,096
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges
Vinogradov, A. A., Yin, Y., & Suga, H. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13178 · Cited by 848
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
“However, insulin detemir binds to HSA with an affinity of ~1 3 10(5) l/mol (22), from which it can be calculated that insulin detemir is 93.”
BackgroundSelf-citationKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
Insulin‐associated weight gain in diabetes – causes, effects and coping strategies
Russell‐Jones, D., & Khan, R. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00686.x · Cited by 557
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Self-citationThe Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429
Self-citationLiu, Z., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00158g · Cited by 419
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 386
Insulin analogues and their potential in the management of diabetes mellitus
Bolli, G. B., Di Marchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 349
Peptide chemistry toolbox – Transforming natural peptides into peptide therapeutics
Erak, M., Bellmann-Sickert, K., Els-Heindl, S., & Beck-Sickinger, A. G. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.012 · Cited by 324
Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin
Tuan Giam Chuang, V., Kragh-Hansen, U., & Otagiri, M. (2002) · Pharmaceutical Research · doi:10.1023/a:1015396825274 · Cited by 295
Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.590 · Cited by 294
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Haak, T., Tiengo, A., Draeger, E., Suntum, M., & Waldhäusl, W. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00373.x · Cited by 277
Plank, J., Bodenlenz, M., Sinner, F., Magnes, C., Görzer, E., Regittnig, W., Endahl, L. A., Draeger, E., Zdravkovic, M., & Pieber, T. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1107 · Cited by 271
Home, P., Bartley, P., Russell-Jones, D., Hanaire-Broutin, H., Heeg, J.-E., Abrams, P., Landin-Olsson, M., Hylleberg, B., Lang, H., Draeger, E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1081 · Cited by 254
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251
The evolution of insulin and how it informs therapy and treatment choices
Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa015 · Cited by 237
“The fact that most of the circulating insulin detemir or insulin degludec is bound to albumin reduces the amount of free drug available for engagement with the insulin receptor, whereas insulin glargine is all available as free drug to bind the insulin receptors (65).”
BackgroundRussell-Jones, D., Simpson, R., Hylleberg, B., Draeger, E., & Bolinder, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90072-0 · Cited by 194
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
“susceptibility to metabolism by DPP-IV [20] and a high degree of albumin binding of liraglutide (as has been shown for other fatty acid derivatives [21, 22]); moreover, after subcutaneous administration, an additional prolongation of the half-life is mediated by slow absorption of liraglutide from the injection site,…”
RetractedZorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K., & Heinis, C. (2017) · Nature Communications · doi:10.1038/ncomms16092 · Cited by 141
Steensgaard, D. B., Schluckebier, G., Strauss, H. M., Norrman, M., Thomsen, J. K., Friderichsen, A. V., Havelund, S., & Jonassen, I. (2013) · Biochemistry · doi:10.1021/bi3008609 · Cited by 86
Self-citationMull, R. W., Harrington, A., Sanchez, L. A., & Tal-Gan, Y. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180518090705 · Cited by 41
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Metadata
- Authors
- Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U. D., Ribel, U., & Markussen, J.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1995-12-15
- Volume
- 312
- Issue
- 3
- Pages
- 725-731
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W1856293447
- Cited by
- 334
- References
- 25
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.